Prostate Cancer UK is expressing frustration at the ongoing lack of access to abiraterone, a life-extending prostate cancer drug, within NHS England. Despite being available in Scotland and Wales for two years, NHS England has restricted its use to only advanced cancer cases. Health Minister Karin Smyth noted the decision was based on affordability, despite the drug demonstrating a significant improvement in survival rates for early-stage patients. The charity stresses that bureaucratic obstacles are greatly impacting patient care and urges for expedited decisions regarding treatment accessibility.
The decision by NHS England to not approve abiraterone in England, despite its availability in Scotland and Wales, showcases a troubling bureaucratic blockade on life-saving treatment.
Prostate Cancer UK expressed anger over the lack of access to abiraterone in England, emphasizing the urgency and dire situation patients face due to treatment delays.
A trial named Stampede has demonstrated that abiraterone significantly improves survival rates for high-risk prostate cancer patients, highlighting the pressing need for its approval.
Health Minister Karin Smyth acknowledged the frustration of patients unable to access abiraterone and confirmed that ministers have urgently sought advice on the matter.
Collection
[
|
...
]